Examkin

Question

Difficulty: Very hardImmunizations and Vaccine-Preventable Diseases

A 9-month-old male infant is brought to the clinic by his parents due to a potential measles exposure. The parents were notified by the infant's daycare that another child in the same room was confirmed to have measles 2 days ago. The infant's medical history is significant for Kawasaki disease, which was successfully treated with high-dose intravenous immunoglobulin (IVIG) (2 g/kg2 \text{ g/kg}) and high-dose aspirin exactly 4 weeks ago. He is currently on low-dose aspirin and is completely asymptomatic. His physical examination is unremarkable. His immunizations are up to date according to the routine schedule, but he has not yet received the measles, mumps, and rubella (MMR) vaccine. Which of the following is the most appropriate next step in management regarding measles prophylaxis for this infant?

  1. Reassure the parents and provide no additional pharmacological prophylaxisAnswer
  2. B
    Administer the measles, mumps, and rubella (MMR) vaccine today
  3. C
    Administer the measles, mumps, and rubella (MMR) vaccine today and schedule a repeat dose at 12 to 15 months of age
  4. D
    Administer intramuscular immune globulin (IGIM) today
  5. E
    Administer both the measles, mumps, and rubella (MMR) vaccine and intramuscular immune globulin (IGIM) today

Answer

The most appropriate next step is to reassure the parents and provide no additional pharmacological prophylaxis, as the infant is already protected by the recent IVIG infusion.
The correct action is to provide no additional pharmacological prophylaxis. The patient received a high-dose IVIG infusion (2 g/kg2 \text{ g/kg}) 4 weeks ago for the treatment of Kawasaki disease. IVIG consists of pooled human IgG, which contains a high titer of neutralizing antibodies against common pathogens, including the measles virus. A dose of 2 g/kg2 \text{ g/kg} confers passive immunity to measles for approximately 11 months. Therefore, this infant is already fully protected from his recent exposure. Furthermore, because of these high levels of circulating passive antibodies, any live-attenuated viral vaccine (such as the MMR vaccine) would be immediately neutralized and rendered completely ineffective. Guidelines dictate that the MMR vaccine should be deferred for 11 months following high-dose IVIG therapy.

Step-by-Step Solution

1
Evaluate the patient's risk profile and standard post-exposure guidelines.
The patient is a 9-month-old exposed to measles 48 hours ago. Standard protocol for immunocompetent infants 6-11 months old is to administer the MMR vaccine if within 72 hours of exposure.
Establishing the baseline guideline is necessary before applying modifications for the patient's specific medical history.
2
Analyze the impact of the patient's recent treatment for Kawasaki disease.
The infant received high-dose IVIG (2 g/kg2 \text{ g/kg}) 4 weeks ago. IVIG is pooled plasma that contains a high concentration of passive IgG antibodies, including neutralizing antibodies against measles.
Recent administration of blood products or immunoglobulins heavily alters immunization protocols.
3
Determine if the MMR vaccine can be given for prophylaxis.
The MMR vaccine cannot be given. The massive pool of passive IgG from the IVIG will immediately neutralize the live-attenuated vaccine virus, making the vaccine ineffective. MMR must be delayed for 11 months following a 2 g/kg2 \text{ g/kg} dose of IVIG.
Live-attenuated viral vaccines are highly sensitive to circulating passive immunity.
4
Determine if another form of prophylaxis, such as IGIM, is required.
No additional prophylaxis is needed. The half-life of IVIG and the massive dose given (2 g/kg2 \text{ g/kg}) provide sufficient circulating measles neutralizing antibodies for approximately 11 months. The infant is already fully protected against the current exposure.
Synthesizing the interaction between the previous treatment and the current exposure reveals that the patient is inherently protected, preventing unnecessary medical intervention.

Key Concept

Interaction between passive immunization (IVIG) and live-attenuated vaccines, and the duration of protection conferred by high-dose IVIG.
Estimated Time:1m 30s
Rate this question

Topics

Immunizations and Vaccine-Preventable Diseases

More questions from this topic